Procedure for Nicotine Replacement Therapy on Inpatient Units
|
|
- Laurence Lionel Wiggins
- 6 years ago
- Views:
Transcription
1 Procedure for Nicotine Replacement Therapy on Inpatient Units PROCEDURE NO CL 005????? DATE RATIFIED December 2014 REVIEW DATE December 2017 APPROVED BY Drugs and Therapeutics ACCOUNTABLE DIRECTOR Chief Pharmacist AUTHOR Lead Pharmacist Procedure Statement/Key Objective: To ensure that all those who smoke have immediate access to Nicotine Replacement Therapy on admission To ensure that Nicotine Replacement Therapy is used safely and effectively Date of issue: 9 th Dec 2014 Page 1 of 15
2 Executive Summary Trust Procedure: Information Subject: Nicotine Replacement Therapy on Inpatient Units Applicable to: All inpatient units Key Procedure Issues: To ensure that all those who smoke have immediate access to Nicotine Replacement Therapy on admission To ensure that Nicotine Replacement Therapy is used safely and effectively Date Issued: December 2014 Dates Procedure Reviewed: n/a Next Review Date: December 2017 Procedure written by/lead: Procedure Lead Monitoring Arrangements: Approved by: Authorised by: Signature: Related Documents: Links to CQC outcomes Lead Pharmacist, Central Lancashire Lead Pharmacist, Central Lancashire Drugs and Therapeutics Committee Smoke Free Working Party Drugs and Therapeutics Committee Drugs and Therapeutics Committee Nicotine Management Policy Policy for the Management of All Aspects of Medication Procedure for the Prescribing of Medication Procedure for the Administration of Medicines 9 Acknowledgements: Large sections of this procedure are taken directly from the All Wales Guide Pharmacotherapy for Smoking Cessation developed by the All Wales Medicines Strategy Group. Date of issue: 9 th Dec 2014 Page 2 of 15
3 Table of Contents 1.0 Introduction Scope Duties Definitions The Procedure Training Monitoring (including Standards) Associated Documents References... 9 Appendix 1 Flowchart of process following admission Appendix 2 Nicotine Replacement Therapy Assessment and Administration Record Appendix 3 summary of cautions in the use of NFT in special populations Appendix 4 BNF Date of issue: 9 th Dec 2014 Page 3 of 15
4 1. Introduction Both behavioural support and pharmacotherapies are effective in helping people to stop smoking. Combining both treatment approaches is recommended where possible. Nicotine replacement therapy (NRT), varenicline and bupropion are the three forms of pharmacotherapy that are licensed for use in the UK to assist with smoking cessation. A Cochrane network meta-analysis concluded that each of these improves the chances of quitting. Combination NRT (the use of an immediaterelease formulation plus patches) is as effective as varenicline, and more effective than single types of NRT. The aim of using NRT is to reduce withdrawal symptoms by providing some of the nicotine that would be obtained from cigarettes, without providing the harmful chemicals present in tobacco smoke. NRT delivers nicotine to the body but at a lower dose and slower rate compared with smoking. There are eight different types of NRT formulations available (patches, gum, lozenges, sublingual tablets, inhalator, oral spray, oral films, and nasal spray) and a variety of strengths. This offers a variety of approaches to best match individual smokers needs and preferences. All formulations of NRT have similar effectiveness. Therefore, the choice of NRT depends largely on: Patient preference Previous patient experience of the type of formulation(s), if any, tried before Contraindications, cautions and the potential for adverse effects Patients with a high level of nicotine dependence, or those who have failed with NRT previously, may benefit from using combination NRT through use of an immediaterelease preparation and patches to achieve abstinence. Level 2 trained smoking champions will be available on mental health inpatient wards to support patients, assess the most suitable form and formulation of pharmacotherapy to support smoking cessation and advise prescribers so treatment can be prescribed on the inpatient prescription chart. Level 2 training covers the treatment options available, and the differences, advantages and disadvantages of each formulation of NRT, varenicline and bupropion. At Longridge Hospital, GPs will be responsible for prescribing pharmacotherapy Given contraindications of bupropion in certain mental illnesses and potential interactions with psychotropic medication bupropion will not be prescribed to aid smoking cessation within Lancashire Care NHS Foundation Trust (LCFT) Given the anticipated delay in assessment by a level 2 trained champion and the fact that a prescription chart may not be written immediately on admission, this procedure is designed to support registered nurses and prescribers in the assessment and administration of combination NRT immediately on admission and for up to 72 hours thereafter. Following consultation with Stop Smoking Services, a decision has been taken that NRT patches and lozenges will be the combination therapy offered immediately post-admission. This procedure therefore only considers nicotine Date of issue: 9 th Dec 2014 Page 4 of 15
5 patches with nicotine lozenges. A flowchart of the process following admission is included in appendix Scope This procedure applies to all inpatient units and staff working within them and becomes operational on 1 st January Duties LCFT is responsible for ensuring that service users have access to pharmacological treatments which will support and aid smoking cessation 3.1. Senior Managers, Ward Managers, and Team Leaders are required to: Ensure all staff and service users are aware of and can access this procedure Ensure Level 2 trained staff have time to fulfil their responsibilities in relation to the assessment of patients for NRT or varenicline 3.2 All members of the inpatient multidisciplinary team are responsible for: Familiarising themselves with the procedure Adhering to and implementing the procedure. Seeking the advice of the stop smoking service or medicines management team when appropriate Being aware of side effects to monitor Monitoring the patient in accordance with the procedure and any additional guidance from Level 2 smoking champions or prescribers 3.3. The Pharmacy Team are responsible for: 4. Definitions Ensuring stocks of nicotine patches and lozenges are available on the ward Reviewing stock levels according to demand Responding to queries from nursing staff and prescribers in relation to this procedure Nicotine Replacement Therapy- a tobacco cessation method intended to reduce nicotine cravings and ease the symptoms of withdrawal by substituting another source of nicotine, such as a specially formulated lozenge, gum, nasal spray, inhalant, or skin patch for tobacco products. 5. The Procedure 5.1. On admission patients must be asked whether they smoke. If they do smoke, advise about the nicotine management policy in place and consider whether they have the capacity to consent to pharmacotherapy to support smoking cessation. Date of issue: 9 th Dec 2014 Page 5 of 15
6 Should they lack capacity to consent then the necessary safeguards must be progressed in line with the mental capacity act Ask whether they would like nicotine replacement therapy to control any nicotine withdrawal symptoms. If they confirm that they would like access to NRT, advise them that they will be assessed for a NRT patch with supplementary lozenges immediately pending a more detailed assessment by a specially trained member of staff If the patient indicates that they would like NRT, take a copy of the NRT assessment and administration form (Appendix 2) and see whether they are eligible for the patch and lozenges. Whilst combination therapy is preferred, should patients have a preference to use a patch or lozenges on their own then this will also be facilitated This form is only for use in the first 72 hours following admission, but should be suspended as soon as a Level 2 smoking champion has assessed the patient and the recommended product/s have been prescribed on the in-patient prescription chart by a prescriber..level 2 smoking champions will consider whether the person is best placed remaining on a patch with lozenge or switching to an alternative product e.g. patch with inhalator, oral sprays or films, varenicline Cautions and Contraindications. Most of the health warnings associated with NRT also apply to continued smoking, but the risks of continued tobacco smoking outweigh any risks of using NRT preparations in virtually all situations. Before using NRT in those with acute cardiovascular events, swallowing difficulties, pregnancy or breastfeeding refer to a prescriber or level 2 smoking champion for further advice. Document the advice given in the clinical record including the name of the person who gave the advice NRT can be considered for all people attempting to quit smoking, including pregnant and breast-feeding women (but see people), and young people aged 12 to 18 years old. All forms of NRT can be used by patients with stable cardiovascular disease, but should be used with caution in those in hospital for acute cardiovascular events. The use of NRT in pregnancy is considered preferable to the continuation of smoking, but should be used only if smoking cessation without NRT fails. Intermittent therapy is preferable to patches, but avoid liquorice-flavoured products. Patches may be appropriate if pregnancy-related nausea and vomiting is a problem. If patches are used they should be removed at night before going to bed. Intermittent therapy is preferable for breast-feeding women. For the purposes of this procedure referral to a prescriber is only required if any of the conditions specified on the Nicotine Replacement Therapy Assessment and Administration Record apply (Appendix 2). Further information on specific cautions for NRT is provided in Appendix 3. Lozenges would not be advised in those with known/assessed swallowing difficulties Date of issue: 9 th Dec 2014 Page 6 of 15
7 If none of the cautions apply, then remove a NRT patch from stock and administer this. Advise the patient that there are also lozenges available should they need additional NRT. Record administration of administered NRT on the form and staple the form to the prescription chart in the section reserved for consent to treatment documentation, or at Longridge the section of the prescription chart used to record intravenous infusions. Record issue of any NRT through any stock level records that may be in use on the ward If any of the cautions apply then speak to a prescriber about use of NRT. If the prescriber approves this, make a daily entry in the clinical record indicating the name of the prescriber consulted and advice given 5.5. Drug Interactions. Tobacco smoking increases the metabolism of some medicines by stimulating the hepatic enzyme CYP1A2. Further information is provided in the UK Medicines Information Q&A Which medicines need dose adjustment when a patient stops smoking? A summary of interactions from this document deemed to be of moderate or high clinical relevance is included in Appendix 4. Moderate to high clinically relevant interactions may result with NRT and warfarin, theophylline, chlorpromazine, clozapine, olanzapine, methadone and insulin requiring increased monitoring and possible dose reductions. The full document including interactions of no/low clinical relevance can also be accessed via the link below or on the prescribing and monitoring section of the pharmacy intranet page: %20&%20A/NW%20QA136.4%20Smoking%20and%20drug%20interactions.doc When smoking is discontinued, the dose of these medicines, in particular theophylline, cinacalcet, ropinirole, and some antipsychotics (including clozapine, olanzapine, chlorpromazine and haloperidol), may need to be reduced. Regular monitoring for increased side effects of the medication is advised and prescribers should be contacted if concerns arise. Should patients be taking any of these medications, prescribers or level 2 smoking cessation champions should inform nursing staff of the additional monitoring required for treatment emergent side effects once they have assessed the patient and prescribed further treatment. Plasma level monitoring is indicated where clozapine is prescribed in line with the Trust Guidelines For Monitoring Clozapine Plasma Levels. Clozapine plasma levels should be repeated one to two weeks after stopping smoking unless treatment emergent side effects indicate earlier monitoring is required. Levels can then be compared with those taken prior to smoking cessation If the patient resumes smoking after discharge and the dose of clozapine was reduced in response to smoking cessation, then the dose will likely need to be increased again. This needs to be considered as part of the discharge planning process. Clozapine levels should be repeated one to two weeks after smoking resumes. Date of issue: 9 th Dec 2014 Page 7 of 15
8 5.6. Side Effects. Most adverse effects experienced with NRT are not serious and are similar to the effects experienced from nicotine obtained by smoking. Minor adverse effects are common with NRT use, particularly in patients using high-strength formulations. They usually improve with time but treatment may need to be reviewed if they continue or become troublesome. However, patients may confuse the side effects of NRT with nicotine withdrawal symptoms. Common symptoms of nicotine withdrawal include malaise, headache, dizziness, sleep disturbance, coughing, influenza-like symptoms, depression, irritability, increased appetite, weight gain, restlessness, anxiety, drowsiness, mouth ulcers, decreased heart rate, and impaired concentration. Common adverse effects of NRT include headache, dizziness, coughing, and gastrointestinal disturbances. Palpitations may occur and, rarely, allergic reactions (including angioedema) and (very rarely) reversible atrial fibrillation. Mild local reactions are common on initiation of NRT because of the irritant effect of nicotine. Minor skin irritation at the application site(s) of patches may occur. If the skin reaction becomes more severe or more widespread, treatment with patches should be discontinued. Dry mouth, sleep disturbances including abnormal dreams. Chest pain, sweating, myalgia and arthralgia have been reported with use of NRT patches Gastrointestinal disturbances are common with oral forms of NRT and may be caused by swallowed nicotine; nausea, vomiting, dyspepsia, and hiccupping occur most frequently. Common side effects of lozenges include dry mouth, increased salivation, mouth ulcers, and sore mouth or throat. Less commonly: thirst, taste disturbance, gingival bleeding, and halitosis may occur. Patients with assessed/known risks re swallowing should not receive lozenges 6. Training All members of the inpatient multidisciplinary team are required to read the procedure and direct any questions to the ward pharmacist or ward managers 7. Monitoring Completion of the NRT assessment and administration form will be assessed as part of the annual prescription chart audit 8. Associated Documents Nicotine Management Policy Policy for the Management of All Aspects of Medication Procedure for the Prescribing of Medication Procedure for the Administration of Medicines Trust Guidelines for Monitoring Clozapine Plasma Levels Date of issue: 9 th Dec 2014 Page 8 of 15
9 9. References NICE (2013) Smoking cessation in secondary care: acute, maternity and mental health services. Public health guidance 48 (accessed ) Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database of Systematic Reviews 2012; (10). Cahill K, Stevens S, Perera R et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis (Review). Cochrane Database of Systematic Reviews 2013; (5). All Wales Medicines Strategy Group. All Wales Guide: Pharmacotherapy for Smoking Cessation. July British Medical Association, Royal Pharmaceutical Society. British National Formulary. No National Institute for Health and Care Excellence. Public Health Guidance 26. Quitting smoking in pregnancy and following childbirth Medicines Q&A Which medicines need dose adjustment when a patient stops smoking? From the NHS Evidence website Date of issue: 9 th Dec 2014 Page 9 of 15
10 Appendix 1. Flowchart of process following admission Ask Patient on admission if they smoke If patient smokes Explain the Nicotine Management Policy and ask if they would like access to NRT. Consider capacity to consent and best interest test if unable to consent NRT declined Inform the patient that they should ask staff for NRT should they change their mind NRT requested Is there a level 2 trained smoking champion currently on the unit? YES Smoking champion assess patient and recommends pharmacotherapy. Entry made in clinical record outlining advice to prescriber NO Is there a prescriber currently on the unit? NO Registered nurse assesses suitability for patches and lozenges using this procedure Patient not suitable YES Patient suitable Prescriber writes on the prescription chart either:- Pharmacotherapy recommended by smoking champion if they agree with one recommendation OR Patches and lozenges as outlines n the procedure pending assessment by level 2 trained smoking advisor (where available) Registered nurse completes the Nicotine Replacement Therapy Assessment and Administration Record. This is stapled to the prescription chart and is used until a prescriber attends the unit to admit the patient and write up medication and NRT. The form can be used for a maximum period of 72 hours Prescriber is contacted for advice Date of issue: 9 th Dec 2014 Page 10 of 15
11 Appendix 2 Nicotine Replacement Therapy Assessment and Administration Record FOR USE DURING THE FIRST 72 HOURS OF ADMISSION ONLY WARD PATIENT NAME NHS NUMBER Nicotine Patches Nicotine patches should not be placed on broken skin and should be used with caution in patients with skin disorders. Refer to a prescriber if the patient is pregnant or breastfeeding. Monitor blood glucose closely if the patient has diabetes mellitus Dose: 21mg/24 hours if patient smokes more than 10 cigarettes per day 14mg/24 hours if patient smokes less than 10 cigarettes per day After 24 hours the used patch should be removed and a new patch applied to a fresh skin site. Skin sites should not be reused for at least seven days. Use of the patch over 24 hours is recommended to optimise the effect against morning craving. Patches may be removed before going to bed if there is an adverse effect on sleep. Date Time Strength of patch (14mg or 21mg) SIGNATURE PRINT NAME Nicorette cool Lozenges Refer to a prescriber if the patient has oesophagitis, oral or pharyngeal inflammation, gastritis, or gastric/peptic ulcers, is pregnant or breastfeeding. Monitor blood glucose closely if the patient has diabetes mellitus Dose: Patient smokes less than 20 cigarettes per day - 2mg lozenge PRN. Maximum of 8 in 24 hours Patient smokes more than 20 cigarettes per day - 4mg lozenge PRN. Maximum of 8 in 24 hours The lozenge should be placed in the mouth and allowed to dissolve. Periodically, the lozenge should be moved from one side of the mouth to the other, and repeated, until the lozenge is completely dissolved. The lozenge should not be chewed or swallowed. Food or drink should not be consumed while a lozenge is in the mouth. Date Time Strength 2mg/4mg SIGNATURE Date Time Strength 2mg/4mg SIGNATURE Date of issue: 9 th Dec 2014 Page 11 of 15
12 Appendix 3. SUMMARY OF CAUTIONS IN THE USE OF NRT IN SPECIAL POPULATIONS Special population Pregnant women Breast-feeding women Cardiovascular disease Diabetes mellitus Hepatic impairment Renal impairment Predisposition to seizures Phaeochromocytoma Uncontrolled hyperthyroidism NRT NRT use in pregnancy is preferable to the continuation of smoking, but should only be used if smoking cessation without NRT fails. Intermittent therapy is preferable to patches. Avoid liquoriceflavoured NRT. Patches are useful, however, if the patient is experiencing pregnancy-related nausea and vomiting. If patches are used, they should be removed before bed. Nicotine from NRT is present in breast milk; however, the amount to which the infant is exposed is small and less hazardous than second-hand smoke. Intermittent therapy is preferred. Caution in use with haemodynamically unstable patients hospitalised with severe arrhythmias, myocardial infarction, or cerebrovascular accident. Initiation should only be under medical supervision. If there is a clinically significant increase in cardiovascular or other effects attributable to nicotine, the dose should be reduced or discontinued. Care in use in patients with diabetes mellitus. Blood glucose concentration should be monitored closely while using NRT. Caution in use with moderate to severe hepatic impairment Caution in use with severe renal impairment. Potential risks and benefits of NRT should be considered before use in patients taking anticonvulsant therapy or with a history of epilepsy as cases of convulsions have been reported in association with nicotine Caution in use Caution in use Date of issue: 9 th Dec 2014 Page 12 of 15
13 Appendix 4 BNF category/ Drug name Nature of interaction Clinical relevance Action to take when stopping smoking Warfarin Theophylline Warfarin is partly metabolised via CYP1A2. An interaction with smoking is not clinically relevant in most patients. The dose of warfarin is adjusted according to a patient s INR (International Normalised Ratio). Theophylline is metabolised principally via CYP1A2. Smokers need higher doses of theophylline than nonsmokers due to theophylline s shortened half-life and increased elimination. Some reports suggest smokers may need twice the dose of non-smokers. Moderate High If a patient taking warfarin stops smoking, their INR might increase so monitor the INR more closely. Advise patients to tell the physician managing their anticoagulant control that they are stopping smoking. Monitor plasma theophylline concentrations and adjust the dose of theophylline accordingly. The dose of theophylline may need to be reduced by about one quarter to one third one week after withdrawal. However, it may take several weeks for enzyme induction to dissipate. Monitor theophylline concentration periodically. Advise the patient to seek help if they develop signs of theophylline toxicity such as palpitations or nausea Chlorpromazine Chlorpromazine is metabolised principally via CYP1A2. Smokers have lower serum levels of chlorpromazine compared with non-smokers. A case report describes a 25 year old patient with schizophrenia who experienced increased adverse effects of chlorpromazine (sedation and dizziness) and increased plasma chlorpromazine levels after abruptly stopping smoking. Moderate Be alert for increased adverse effects of chlorpromazine (e.g. dizziness, sedation, extrapyramidal symptoms). If adverse effects occur, reduce the dose as necessary. Date of issue: 9 th Dec 2014 Page 13 of 15
14 BNF category/ Drug name Nature of interaction Clinical relevance Action to take when stopping smoking Clozapine Clozapine is metabolised principally via CYP1A2 and clearance is increased in smokers. Serum clozapine levels are reduced in smokers compared with nonsmokers; smokers may need higher doses. There have been case reports of adverse effects in patients taking clozapine when they have stopped smoking. High Monitor serum drug levels before stopping smoking and one or two weeks after stopping smoking. Be alert for increased adverse effects of clozapine. If adverse effects occur, reduce the dose as necessary Olanzapine Olanzapine is metabolised principally via CYP1A2 and clearance is increased in smokers. Serum olanzapine levels are reduced in smokers compared with nonsmokers; smokers may need higher doses. There have been case reports of adverse effects in patients taking olanzapine when they have stopped smoking. High Be alert for increased adverse effects of olanzapine (e.g. dizziness, sedation, hypotension). If adverse effects occur, reduce the dose as necessary Methadone Methadone is metabolised via isoenzymes including CYP1A2. There has been a case report of respiratory insufficiency and altered mental status when a patient taking methadone for analgesia stopped smoking. Moderate Be alert for signs of opioid toxicity and reduce the methadone dose accordingly Insulin Smoking is associated with poor glycaemic control in patients with diabetes. Smokers may require higher doses of Moderate If a patient with insulindependent diabetes stops smoking, their dose of insulin may need to be reduced. Advise the patient to be alert Date of issue: 9 th Dec 2014 Page 14 of 15
15 BNF category/ Drug name Nature of interaction Clinical relevance Action to take when stopping smoking insulin but the mechanism of any interaction is unclear. for signs of hypoglycaemia and to test their blood glucose more frequently. Date of issue: 9 th Dec 2014 Page 15 of 15
Formulary and Prescribing Guidelines
Formulary and Prescribing Guidelines SECTION 17: NICOTINE REPLACEMENT THERAPY 17.1 Introduction These guidelines should be used in conjunction with SEPT No Smoking Policy (HRP20) and for service users
More informationSECTION 17: NICOTINE REPLACEMENT. Formulary and Prescribing Guidelines
SECTION 17: NICOTINE REPLACEMENT Formulary and Prescribing Guidelines 17.1 Introduction These guidelines should be used in conjunction with EPUT No Smoking Policy (HRP20) for service users who are 12 years
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Derbyshire Formulary for Nicotine Replacement Therapy (NRT) 1. Supporting Smokers to stop smoking The most effective method to quit smoking is by quitting
More informationClinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services SMOKING CESSATION Introduction NICE recommends that Nicotine Replacement Therapy (NRT), bupropion [Zyban ] and
More informationPGD5717. Director of Quality & Clinical Performance. Therèsa Moyes
PGD5717 Patient Group Direction Administration of Nicotine Lozenges 4mg, Sublingual Tablets 2mg or Mouth Spray By Registered Nurses employed as by South Staffordshire & Shropshire Healthcare Foundation
More informationJob Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due
More informationTitle: Approved By: Applicable to: Group D&T section of the AMD Dept./ Division Only No Directorate Only: No Trust-wide No
Title: CLINICAL GUIDELINES ID TAG Smoking Cessation Guideline for the Prescribing, Issue and Administration of Nicotine Replacement Therapy on Inpatient Wards Lyn Watt Pharmacy Patient Services Manager
More informationPatient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists
Patient Group Direction for the Supply of Varenicline (Champix ) This Patient Group Direction (PGD) is a specific written instruction for the supply of varenicline to groups of patients who may not be
More informationPatient Group Direction for the Supply of Nicotine Replacement Therapy, (NRT) (Smoking Cessation Service for Pharmacies in Kent)
Patient Group Direction for the Supply of Nicotine Replacement Therapy, (NRT) (Smoking Cessation Service for Pharmacies in Kent) Written by: Marion Walton, Pharmacist Advanced, Adult Services Date: February
More informationfor adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services
The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service
More informationPATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE GENERAL POLICY 2 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE 4 STANDING ORDER
More informationSmoking Cessation Pharmacotherapy Guidelines
Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence
More informationAWMSG members are asked to consider the update of the All Wales Guide: Pharmacotherapy for Smoking Cessation for endorsement.
Enclosure No: Agenda Item No: Author: Contact: 10/AWMSG/0218 15 All Wales Guide: Pharmacotherapy for Smoking Cessation Rosemary Allgeier, Principal Pharmacist in Public Health, Public Health Wales Tel:
More informationPATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN NHS LANARKSHIRE (Approved May 2014 - Review Date May 2016) GENERAL POLICY PATIENT GROUP DIRECTION
More informationProtocol for the Direct Supply of Nicotine Replacement Therapy by Competent Non-Clinical Advisors of The Stop Smoking Service in Norfolk
Appendix B Protocol for the Direct Supply of Nicotine Replacement Therapy by Competent Non-Clinical Advisors of The Stop Smoking Service in Norfolk Document Control Document name Protocol for the direct
More informationStop smoking products guidance
Stop smoking products guidance Ref: Status: Approved Stop smoking products guidance Page 1 of 15 Approval date: 22 November 2018 Contents 1. Purpose... 3 2. Related documents... 3 3. Guidance... 3 3.1
More informationA new model for prescribing varenicline
Pharmacist Independent Prescribers in partnership with A new model for prescribing varenicline Dear Stop Smoking Advisor You will be aware of the stop smoking drug varenicline that goes under the brand
More informationThis letter authorises the extended use of the following protocol until 1st September 2018:
NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date: 22nd March 2018 Our Ref: FA/NRTComm/MGPG/Mar18 Enquiries to: Frances Adamson Extension: 56689 Direct Line: 01224
More informationCAMBRIDGESHIRE & PETERBOROUGH STOP SMOKING SERVICE S. Stop Smoking Pharmacological Products Guidance
CAMBRIDGESHIRE & PETERBOROUGH STOP SMOKING SERVICE S Stop Smoking Pharmacological Products Guidance This guidance is for use by Cambridgeshire Stop Smoking Service (CAMQUIT), Peterborough Stop smoking
More information5. Offer pharmacotherapy to all smokers who are attempting to quit, unless contraindicated.
0 11 Key Messages 1. Ask and document smoking status for all patients. 2. Provide brief advice on quit smoking at every visit to all smokers. 3. Use individual, group and telephone counselling approaches,
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE
More informationPrescribing guidance in. Smoking Cessation March 2011
Prescribing guidance in Smoking Cessation March 2011 The aim of this guidance is to update previous prescribing guidance (2007) ensuring that there is a consistent approach throughout Dumfries & Galloway
More informationPROTOCOL FOR A NICOTINE REPLACEMENT THERAPY (NRT) VOUCHER SCHEME
PROTOCOL FOR A NICOTINE REPLACEMENT THERAPY (NRT) VOUCHER SCHEME PREPARED BY: Kirklees Public Health on behalf of the Council of the Borough of Kirklees FIRST ISSUED: 1 st April 2017 TO BE REVIEWED: 31
More informationGuidelines for. Nicotine Replacement Therapy. Issuing of Vouchers. For use by the Stop Smoking in Pregnancy Service
Guidelines for Nicotine Replacement Therapy Issuing of Vouchers For use by the Stop Smoking in Pregnancy Service DOCUMENT CONTROL: Version: 1 Ratified by: Clinical Effectiveness Committee Date ratified:
More informationBest Practice for Smoking Cessation: Pharmacotherapy. Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree
Best Practice for Smoking Cessation: Pharmacotherapy Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree Why is it so hard to quit? People who smoke aren t weak
More informationBrighton and Hove Pharmacy Enhanced Service (PLES 02)
Brighton and Hove Pharmacy Enhanced Service (PLES 02) Smoking Cessation Service (2007/08) This enhanced service is aimed at clients who are non-complex cases and would like to be supported and be managed
More informationNicotine Replacement Therapy (NRT).
Nicotine Replacement Therapy (NRT). Information for smokers 1 What is NRT? The aim of Nicotine Replacement Therapy (NRT) is to reduce the withdrawal symptoms associated with nicotine addiction by replacing
More informationSmoking and Nicotine Replacement Therapy (NRT) Lec:5
Smoking and Nicotine Replacement Therapy (NRT) Lec:5 Tobacco use remains the single largest preventable cause of mortality. Cigarette smoke is a complex mixture of an estimated 4800 compounds. Approximately
More information6.2 Overview of disease epidemiology
6.2 Overview of disease epidemiology WHO has calculated that every second smoker will die early because of smoking and in average a smoker will lose 7-8 years of lifetime. Today, tobacco use causes 1 in
More informationNicotine Replacement Therapy, Zyban and Champix. Name of presentation
Nicotine Replacement Therapy, Zyban and Champix Nicotine Replacement Therapy (NRT) - Rationale for use Nicotine is highly addictive and causes unpleasant withdrawal symptoms which often undermine a quit
More informationNicAssist 15 mg Inhalator (Nicotine)
Information for the user NicAssist 15 mg Inhalator (Nicotine) Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription to help
More informationVersion Number: 5. Patient Group Direction drawn up by: Chief Pharmacist - Strategy. Group direction authorised by:
PATIENT GROUP DIRECTION (PGD) FOR THE INPATIENT ADMINISTRATION OF ORAL LORAZEPAM TO WORKING AGE AND OLDER PEOPLE (includes persons in a Place of Safety suite) Version Number: 5 Patient Group Direction
More informationNicotine Replacement Therapy (NRT) Guidelines
Document level: Trustwide (TW) Code: MP14 Issue number: 5 Nicotine Replacement Therapy (NRT) Guidelines Lead executive Authors details Type of document Target audience Document purpose Medical Director
More informationPATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets. By: Accredited Pharmacists
PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets By: Accredited Pharmacists In: Community Pharmacies in [insert area] accredited by [insert council] It is the responsibility of
More informationNHS FORTH VALLEY Stop Smoking Guidance
NHS FORTH VALLEY Stop Smoking Guidance Date of First Issue 28/06/2012 Approved 28/06/2012 Current Issue Date 22/01/2018 Review Date 22/01/2021 Version Version 2 EQIA 01/05/2018 Author / Contact Scott Robertson,
More informationBoots NicAssist Fruit Fresh Gum (Nicotine)
Information for the user Boots NicAssist Fruit Fresh Gum (Nicotine) Boots NicAssist Fruit Fresh 2 mg Gum Boots NicAssist Fruit Fresh 4 mg Gum Read all of this leaflet carefully because it contains important
More informationPatient Group Direction. for the supply of. by registered community pharmacists for. smoking cessation in combination with motivational.
\f,pubiic,j Dorset Health This Patient Group Direction (PGD)must only be used by registered community pharmacists who have been named and authorised by their organisation to practice under it. The most
More informationPackage leaflet: Information for the user. Nicovel Frukt 4 mg medicated chewing-gum. nicotine
Package leaflet: Information for the user Nicovel Frukt 2 mg medicated chewing-gum Nicovel Frukt 4 mg medicated chewing-gum nicotine Read all of this leaflet carefully before you start using this medicine
More informationIMPORTANT POINTS ABOUT MEDICATIONS
IMPORTANT POINTS ABOUT MEDICATIONS The U.S. Food & Drug Administration (FDA) advises that there are significant health benefits to quitting smoking. The health benefits of quitting smoking include a reduction
More informationBackground. Abstinence rates associated with varenicline
What are the range of abstinence rates for varenicline for smoking cessation? Do they differ based on treatment duration? Are there any studies utilizing 3-4 months of varenicline treatment? Background
More informationSmokefree Wiltshire. Information leaflet. Planning to quit? Find the right support for you.
Smokefree Wiltshire Information leaflet Planning to quit? Find the right support for you www.wiltshire.gov.uk/smokefree Support for smokers Smokefree Wiltshire offers tailored stop smoking support for
More informationNicAssist 2 mg Lozenge (Nicotine)
Information for the user NicAssist 2 mg Lozenge (Nicotine) Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription to help
More informationSmoking cessation therapy
Appendix 1 Smoking cessation therapy Q. Can a dentist prescribe medications for smoking cessation? A. Yes. Dentists are allowed and are encouraged to help patients with smoking cessation by counseling
More informationMy Mask. I keep it all inside. Because I d rather. The pain destroy me. Than everyone else. Anon.
My Mask KL I keep it all inside Because I d rather The pain destroy me Than everyone else. Anon. 43 K. N. Roy Chengappa, M.D., FRCPC Professor of Psychiatry, University of Pittsburgh School of Medicine,
More informationSMOKING CESSATION IS HARD
POWER TO BREAK THE HOLD OF NICOTINE ADDICTION 1 SMOKING CESSATION IS HARD Most smokers try to quit 5-7 times before they are successful. 2 Why is it so hard to quit? Typical withdrawal symptoms from stopping
More informationSMART STEPS towards a tobacco-free life
SMART STEPS towards a tobacco-free life Ready to Quit Smoking? You decide when. We ll show you how. Smart steps... Ready to Put Tobacco Behind You? Congratulations on deciding to quit! Quitting tobacco
More informationHelping People Quit Tobacco
Helping People Quit Tobacco Peter Selby MBBS, CCFP, MHSc, ASAM Associate Professor, University of Toronto Clinical Director, Addictions Program, CAMH Principal Investigator, OTRU Disclosures! Grants/research
More informationDispensing of Nicotine Replacement Therapy (NRT)
Simcoe Muskoka District Health Unit Print Version Medical Directive Number: Topic: Dispensing of Nicotine Replacement Therapy (NRT) Revised: October 2011 Approved: May 21, 2007 Description Nicotine Replacement
More informationMMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA
MMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA Page 1 of 11 Table of Contents Why we need this Guideline... 3 What the Policy is trying to do... 3 Which stakeholders have been
More informationOutpatient Tobacco Addiction Treatment Pathway Additional Notes
Outpatient Tobacco Addiction Treatment Pathway Additional Notes First Line: Varenicline (provide in conjunction with counselling/support, but if such support is refused or is not available, this should
More informationPATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS
PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS Version No: Draft 2 Please note this PGD has been approved by SWYFT Drugs and Therapeutic Committee this is an
More informationIntroduction to pharmacotherapy
Introduction to pharmacotherapy Dr. Shamim Jubayer. Research Fellow Dept. Epidemiology and Research National Heart Foundation Hospital And research Institute Effective tobacco cessation medications The
More informationNicAssist 1mg/spray Mouth Spray Nicotine
Information for the user NicAssist 1mg/spray Mouth Spray Nicotine Read all of this leaflet carefully before you start using this medicine because it contains important information for you. This medicine
More informationpatient group direction
SALBUTAMOL v01 1/12 SALBUTAMOL PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner
More informationSMOKING CESSATION. Recommendations 5As Approach to Smoking Cessation. Stages of Change Assisting the Smoker. Contributor Dr. Saifuz Sulami.
SMOKING CESSATION 08 Recommendations 5As Approach to Intervention Stages of Change Assisting the Smoker Pharmacotherapy Contributor Dr. Saifuz Sulami Advisor Dr. Audrey Tan 79 nhg_guideline_14102010_1112.indd
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationService Specification & Contract Intermediate Stop Smoking Service & Voucher fulfilment - Pharmacy Newcastle
Service Specification & Contract Intermediate Stop Smoking Service & Voucher fulfilment - Pharmacy Newcastle Contents 1. Agreement period 2. Scope 3. Targets 4. Service outline 5. Support for clients using
More informationPatient Group Direction HCC for the supply of varenicline. by registered community pharmacists for. Stopping Smoking in Hertfordshire
This Patient Group Direction (PGD) must only be used by registered community pharmacists who have been named and authorised by their organisation to practice under it. The PGD must only be used in conjunction
More informationCLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES
National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) MMCP05 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION
More informationPATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY Version Number: 5 Patient Group Direction drawn up by: Name Ray Lyon Dr Al Amaladoss
More informationPregnancy and nicotine replacement therapy (NRT) What you need to know
Pregnancy and nicotine replacement therapy (NRT) What you need to know Pregnancy is a great opportunity to stop smoking. Avoiding tobacco is the most important thing a woman can do to improve her health
More informationGuideline scope Smoking cessation interventions and services
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Topic NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Smoking cessation interventions and services This guideline
More informationGuidance for the Management of Smoking Cessation within Sirona Care & Health and Providers in the Community
Guidance for the Management of Smoking Cessation within Sirona Care & Health and Providers in the Community This guidance should be used in close conjunction with the referenced guidelines, in particular
More informationTobacco Dependence Treatment Pathway
Tobacco Dependence Treatment Pathway GUIDELINE VERSION 1 RATIFYING GROUP Drugs and Therapeutics Group (DTG) DATE PUBLISHED January 2017 NEXT REVIEW DATE January 2019 FORMULARY SPONSOR Executive Medical
More informationSmoking. know the facts
Smoking know the facts DID YOU KNOW? In Northern Ireland, 2,300 people die each year from smoking-related illness more than six people per day. Why stop? Smoking is the main cause of illness and early
More informationInhalator Nicotine Replacement Therapy
NICORETTE (NRT) Inhalator Nicotine Replacement Therapy What is NICORETTE? NICORETTE is a range of NRT medicines intended to support you while you give up smoking by relieving withdrawal symptoms and reduce
More informationNumber of records submitted: 14,750 Number of participants: Part 1 = 146 hospitals (120 trusts); Part 2 = 140 hospitals (119 trusts)
British Thoracic Society Smoking Cessation Audit Report Smoking cessation policy and practice in NHS hospitals National Audit Period: 1 April 31 May 2016 Dr Sanjay Agrawal and Dr Zaheer Mangera Number
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationPackage leaflet: Information for the user. Zonnic Mint 2 mg oromucosal powder in pouch Nicotine
Package leaflet: Information for the user Zonnic Mint 2 mg oromucosal powder in pouch Nicotine Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationTobacco Dependence Screening and Treatment in Behavioral Health Settings. Prescribing
Tobacco Dependence Screening and Treatment in Behavioral Health Settings Prescribing GOAL To build the capacity of prescribing clinicians in behavioral health settings to integrate best practices for prescribing
More informationPackage leaflet: information for the user Nicorette Microtab 2 mg sublingual tablets. Nicotine
Nicorette Microtab for packaging containing blister Package leaflet: information for the user Nicorette Microtab 2 mg sublingual tablets Nicotine Read all of this leaflet carefully before you start using
More informationEffective Treatments for Tobacco Dependence
Effective Treatments for Tobacco Dependence Abigail Halperin MD, MPH Director, University of Washington Tobacco Studies Program Ken Wassum Associate Director of Clinical Development and Support Quit for
More informationSHARED CARE PRESCRIBING GUIDELINE
SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply
More informationGuidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults
Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Ref: PHARM-0025-v3 Status: FINAL Document type: Guidelines Guidance on Safe Prescribing of Melatonin Page
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationpatient group direction
DIAZEPAM (RECTAL) v01 1/8 DIAZEPAM (RECTAL) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care
More informationNICOTEX Chewing Gum (Nicotine polacrilex)
Published on: 22 Sep 2014 NICOTEX Chewing Gum (Nicotine polacrilex) Composition NICOTEX Chewing Gum Each piece contains: Nicotine Polacrilex USP (equivalent to Nicotine)... 2 mg or Nicotine Polacrilex
More informationREGIONAL PHARMACY SPECIALIST SMOKING CESSATION SERVICE FEBRUARY A Pharmacist s Guide
REGIONAL PHARMACY SPECIALIST SMOKING CESSATION SERVICE FEBRUARY 2009 A Pharmacist s Guide Aims of the Service The overall aim of the service is to deliver a pharmacy based, one stop specialist smoking
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationSMOKING CESSATION FOR PHARMACY STAFF BRIEF INTERVENTION. February 2016
SMOKING CESSATION FOR PHARMACY STAFF BRIEF INTERVENTION February 2016 SLIDE TITLE THE WELLBEING TEAM Established for 16 years Providers & facilitators of specialist SC interventions Clinically proven to
More informationPackage leaflet: Information for the user. Zonnic Pepparmint 1 mg/spraying oromucosal spray Nicotine
Package leaflet: Information for the user Zonnic Pepparmint 1 mg/spraying oromucosal spray Nicotine Read all of this leaflet carefully before you start using this medicine because it contains important
More informationpatient group direction
ACICLOVIR v01 1/8 ACICLOVIR PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationUpdate on SMOKING CESSATION. Supporting the PHO Performance Programme. 38 BPJ Issue 33
Update on SMOKING CESSATION Supporting the PHO Performance Programme 38 BPJ Issue 33 Key concepts The rate of smoking among New Zealanders is slowly reducing, however more work needs to be done to further
More information1. Describe the benefits of smoking cessation. 2. List the withdrawal symptoms of quitting smoking. Cessation
Time to Butt Out Adil Virani, BSc (Pharm), Pharm D, FCSHP Objectives After this presentation, participants should be able to: 1. Describe the benefits of smoking cessation 2. List the withdrawal symptoms
More informationContinence PGD transdermal oxybutynin Kentera patch 36mg
Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence
More informationSmoking Cessation Medbelle Information Brochure
Smoking Cessation Medbelle Information Brochure Why we prepared this brochure for you Hi, my name is Sarah. I m a cosmetic treatment adviser with Medbelle. Every day, I speak with men and women in the
More informationPatient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018
THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG Lancashire North CCG Fylde & Wyre CCG East Lancashire CCG Change history Version
More informationNICABATE Strips Mint Oral Films 2.5 mg Nicotine CONSUMER MEDICINE INFORMATION
NICABATE Strips Mint Oral Films 2.5 mg Nicotine CONSUMER MEDICINE INFORMATION Please read this information before you start taking this medicine. What is in this leaflet? This leaflet answers some common
More informationPeterborough Nalmefene Pathway Responsibilities for Specialist Services & GP
Peterborough Nalmefene Pathway Responsibilities for Specialist Services & GP INTRODUCTION/BACKGROUND In November 2014 NICE (National Institute of Clinical Excellence) published the Technology Appraisal
More informationpatient group direction
ASPIRIN v01 1/8 ASPIRIN PGD Details Version 1.0 Legal category P Staff grades Approved by Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationSHARED CARE AGREEMENT: MELATONIN (CHILDREN)
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate
More informationCHAMPIX. Deciding to stop smoking. What is in this leaflet. What CHAMPIX is used for. Before you take CHAMPIX
CHAMPIX (tshamp-iks) Varenicline tartrate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about It does not contain all the available information. It does
More informationBuccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus.
Oxfordshire Clinical Commissioning Group, Oxford University Hospitals NHS Trust and Oxfordshire Health NHS Foundation Trust Shared Care Protocol and Information for GPs Buccal Midazolam For the treatment
More informationCENTRE FOR ADDICTION AND MENTAL HEALTH -MEDICAL DIRECTIVE ADMINISTRATION OF NICOTINE REPLACEMENT MEDICATIONS BY REGISTERED NURSES
CENTRE FOR ADDICTION AND MENTAL HEALTH -MEDICAL DIRECTIVE TITLE: ADMINISTRATION OF NICOTINE REPLACEMENT MEDICATIONS BY REGISTERED NURSES POLICY #: D24 ORIGINATOR: Nicotine Dependence Clinic APPROVAL DATE:
More informationNHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Duloxetine. For the Treatment of Pain
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Duloxetine For the Treatment of Pain This information is not intended to replace your doctor s advice.
More informationCLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES
National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) CP11 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION The
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Salbutamol Aerosol Inhaler and salbutamol Nebulised Solution Trust Ref No 1569-34313 Local Ref (optional) Main points the document Treatment of acute
More informationBreaking the Chains of Nicotine Dependence - A Breakthrough Approach
Breaking the Chains of Nicotine Dependence - A Breakthrough Approach Dr Rob Young Senior Lecturer & Consultant Physician Auckland Hospital, New Zealand Smoking Cessation in 2001 Smoking contributes to
More information